Theramed Corporation signs an eight year extension with EUSA Pharma Ltd. for the exclusive right to import, market and distribute COLLATAMP® G in Canada
Hospital-Acquired Infections in the News
Leading Canadian Hospitals Quick to Use New Implantable Antibiotic for Prevention and Treatment of Surgical Infections
New Website Educates Public on the Risks and Prevention of Deadly Surgical Infections
Economic Model Demonstrates Hospital Cost Savings Using Collatamp G
Ontario's Mandatory Public Reporting of Surgical Site Infections Puts SSIs on the Public's Radar
New Implantable Antibiotic Helps Canadian Hospitals Save Lives And Money By Preventing Surgical Infections
FDA Designates Gentamicin Surgical Implant (Collatamp G) as a Fast Track Development Program
Theramed Announces Long-Term Partnership with Canadian Society of Colon and Rectal Surgeons
Bourne Partners Announces the Acquisition of Theramed Corporation
Ontario's Mandatory Public Reporting of Surgical Site Infections Puts SSIs on the Public's Radar
Published Sunday, February 15 2009
TORONTO – Effective April 30, 2009, the Ontario Ministry of Health and Long Term Care is instituting mandatory public reporting of surgical site infection (SSI) rates at all Ontario hospitals. Currently, MRSA and C. difficile rates are also publicly reported.
Most often, reports focus on the MRSA and C. difficile "superbugs" when, in fact, SSIs cost the cash-strapped Canadian healthcare system over $200 million and over 400,000 bed days annually. Paradoxically 40%-60% of all SSIs are considered preventable.
The Ontario Ministry of Health’s decision to institute public reporting of hospital SSI rates now helps elevate the awareness and visibility of surgical site infections to the public, allowing surgical patients to have access to and compare institutional SSI rates.
For Further Information
http://www.health.gov.on.ca/patient_safety/








